Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial

BACKGROUND: Carvedilol is a non-selective, third-generation beta-blocker and is one of the cornerstones for treatment for patients with heart failure and reduced ejection fraction (HFrEF). However, due to its short half-life, immediate-release carvedilol (IR) needs to be prescribed twice a day. Rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Dong-Ju, Park, Chan Soon, Park, Jin Joo, Lee, Hae-Young, Kang, Seok-Min, Yoo, Byung-Su, Jeon, Eun-Seok, Hong, Seok Keun, Shin, Joon-Han, Kim, Myung-A, Park, Dae-Gyun, Kim, Eung-Ju, Hong, Soon-Jun, Kim, Seok Yeon, Kim, Jae-Joong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809818/
https://www.ncbi.nlm.nih.gov/pubmed/29433525
http://dx.doi.org/10.1186/s13063-018-2470-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809818/
https://www.ncbi.nlm.nih.gov/pubmed/29433525
http://dx.doi.org/10.1186/s13063-018-2470-5

Ejemplares similares